GUEST COLUMNISTS

• Avoiding Common Pitfalls In CDMO–Sponsor Relationships Through Integrated Execution Models

  Let's delve into the key pitfalls to avoid when working with a CDMO and the integrated execution model that solves or mitigates these pitfalls before they occur.

• The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process

  Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.

• CDMO Selection: Start With The Relationship, Not The RFP

  Friction often comes from unspoken expectations. Before production begins, treat the combined sponsor-CDMO group as one extended team and intentionally make “how we work together” visible.

• Why FAT Should Confirm Alignment, Not Reveal Its Absence

  In many aseptic fill/finish projects, the factory acceptance test (FAT) has become the first true integration test of the entire project. That is a problem. Here's how to flip that mindset.

• What Reliance, Annex 1, And AI Mean For The Future Of GMP

  EMA’s Brendan Cuddy explains how regulators are adapting oversight to global supply chains, new technologies, and growing operational complexity.

• Applying Contamination Control By Design: A Practical Guide For CDMOs

  This article addresses the three contamination control challenges that are specific to the CDMO environment, provides five practical steps any organization can act on now, and more.

• What To Do About Process Drift In Your Biosimilar's Reference Product

  Biosimilar development often reveals quality drifts in certain lots of the reference biologic. In most cases, quality changes are noncritical, but some drifts can impact CQAs.